A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)

NCT04115189 · clinicaltrials.gov ↗

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma ( mRCC)

Interventions

DRUG: Sunitinib

Sponsor

Pfizer